BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center played a leading role in developing ziftomenib , a first-in-class targeted therapy now approved by the U.S. Food and Drug Administration for adults with relapsed or refractory acute myeloid leukemia (AML).

The approval came on November 13, 2025, following the pivotal phase 1/2 KOMET-001 trial co-led globally by Dr. Eunice Wang , Chief of Leukemia and Benign Hematology at Roswell Park.

"The very first human being in the world to ever take this drug was treated here at Roswell Park," she said. "We believe in bringing cutting edge therapies home to Western New York and Central New York so patients don't have to travel across country during one of the most vulnerable times of their lives."

The drug had shown remarkable promise i

See Full Page